Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pustulotic arthroosteitis (PAO) is a rare chronic inflammatory arthropathy associated with palmoplantar pustulosis (PPP). PAO involves various extra-palmoplantar sites, including spinal lesions. Systemic treatment, including biologics, is required for refractory cases of PAO. We herein report a man diagnosed with PAO who predominantly manifested spinal symptoms. Initial treatment with non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and bisphosphonates achieved a minimal response. Risankizumab, an anti-IL-23 p19 antibody, was subsequently administered, which resulted in significant improvement after the fourth dose, resolving both spinal and cutaneous manifestations. This case report highlights risankizumab as a potential therapeutic option for refractory PAO with spinal involvement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.5979-25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review.
Am J Clin Dermatol
September 2025
Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan.
Background: Ethnic differences in the clinical and molecular features of many immune-mediated dermatoses have been reported, including psoriasis vulgaris and generalized pustular psoriasis. Palmoplantar pustulosis (PPP) is a chronic and relapsing inflammatory skin disease manifesting as crops of sterile pustules over an erythematous base on the palms and soles. To date, ethnic differences in PPP have been rarely studied.
View Article and Find Full Text PDFA Patient with Pustulotic Arthroosteitis with Isolated Spinal Lesions Successfully Treated with Risankizumab: A Case Report.
Intern Med
August 2025
Department of Radiology, St Francisco Hospital, Japan.
Pustulotic arthroosteitis (PAO) is a rare chronic inflammatory arthropathy associated with palmoplantar pustulosis (PPP). PAO involves various extra-palmoplantar sites, including spinal lesions. Systemic treatment, including biologics, is required for refractory cases of PAO.
View Article and Find Full Text PDFImprovement in MRI Findings in Pustulotic Arthro-osteitis Post-tonsillectomy.
J Clin Rheumatol
September 2025
Division of Rheumatology, Teikyo University Medical Center in Chiba, Chiba, Japan.
SAPHO syndrome with bone destruction in the lumbar vertebral endplates: A case report.
Mod Rheumatol Case Rep
July 2025
Department of Orthopaedic Surgery, Toho University Sakura Medical Center, Chiba, Japan.
SAPHO syndrome is a rare inflammatory osteoarticular disorder, which includes autoimmune diseases such as pustulotic arthro-osteitis, inflammatory bowel disease-associated spondyloarthritis, and psoriatic arthritis. There are few reports on the treatment of SAPHO syndrome that presents with bone destruction in the spine. We present a case in which adalimumab (ADA) was administered to treat destruction of the lumbar vertebral endplates caused by SAPHO syndrome.
View Article and Find Full Text PDFEfficacy of granulocyte and monocyte adsorptive apheresis on skin and joint manifestations of palmoplantar pustulosis with pustulotic arthro-osteitis: A multicentric, prospective, observational study.
J Dermatol
April 2025
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Granulocyte and monocyte adsorptive apheresis (GMA) selectively removes activated granulocytes and monocytes from the peripheral blood. In 2012, GMA was approved in Japan as a treatment for generalized pustular psoriasis and localized pustular psoriasis or palmoplantar pustulosis (PPP). Limited evidence from case reports and monocentric studies suggested that GMA is an effective treatment for skin and joint symptoms of PPP with pustulotic arthro-osteitis (PAO).
View Article and Find Full Text PDF